Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family With Sequence Similarity 166, Member A, pseudogene 4 (ENSG00000227711) is a human genomic element classified as a pseudogene, meaning it is a DNA sequence derived from a previously functional gene but now incapable of encoding a protein[4][6]. Pseudogenes often result from gene duplication or retrotransposition followed by disabling mutations, and may retain significant homology to their ancestral gene[4][6]. While most pseudogenes are presumed nonfunctional, some have been shown to exert regulatory effects at the RNA level, but specific functions are not known for this locus[8]. No roles in disease nor interactions with drugs have been reported, and this locus is not used as a biomarker or therapeutic target. As such, it should not be considered a canonical molecular target for pharmacological intervention.
None defined for drugs, as this is not a druggable target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family With Sequence Similarity 166, Member A, pseudogene 4 (None).